Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers Abstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Cash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel i ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bolt To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Bolt between February 5, 2021 and May 14, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BOLT. NEW YORK, Aug. 7, ...

NEW YORK, Aug. 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), of the important September 3, 2024 lead plaintiff deadline. SO WHAT: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

Follow us for updates on LinkedIn, on X, or on Facebook. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) BDC-1001 was less eff ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), of the important September 3, 2024 lead plaintiff deadline. WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class ac ...

If you are a shareholder who suffered a loss, click here to participate. LOS ANGELES, July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. CONTACT: The Schall Law Firm Brian Schall, Esq. ...

Core Viewpoint - Bolt Biotherapeutics, Inc. announced the cessation of development for its drug candidate BDC-1001, shifting focus to BDC-3042 and BDC-4182, which has led to significant stock downgrades and a sharp decline in share price [2][5]. Company Developments - On May 14, 2024, Bolt announced it would stop further development of BDC-1001 due to its failure to meet success criteria, resulting in a workforce reduction of approximately 50% [2]. - The CEO Randall C. Schatzman and CMO Edith Perez will transition to advisory roles as part of the restructuring [2]. Stock Market Reaction - Following the announcement, Bolt's stock price fell by $0.49 per share, a decrease of 37.12%, closing at $0.83 per share on May 15, 2024 [2]. Analyst Reactions - Multiple analysts downgraded Bolt's stock, citing concerns over the commercial prospects of BDC-3042 and BDC-4182, as well as the leadership changes [2]. Legal Context - A class action lawsuit has been filed on behalf of investors who purchased Bolt securities between February 5, 2021, and May 14, 2024, alleging that the company misled investors regarding the effectiveness of BDC-1001 and overstated the prospects of its product pipeline [4][5][8].

SO WHAT: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) BDC-1001, Bolt's immune-stimulating antibody conjugate ("ISAC") designed to target a tumor antigen known as human epidermal growth factor receptor 2 ("HER2") that is often found in cance ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bolt To Contact Him Directly To Discuss Their Options Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP) On May 14, 2024, Bolt announced in a press release that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)," Bolt's lead asset, "and reduce workforce by approximately 50%." Following Bolt's announcement, multiple analysts d ...

Core Points - A class action lawsuit has been filed against Bolt Biotherapeutics, Inc. for misleading statements regarding its product BDC-1001, which is designed to target HER2 in certain cancers [7][8] - The lead plaintiff deadline for the class action is September 3, 2024, and investors who purchased Bolt securities during the Class Period (February 5, 2021 to May 14, 2024) may be entitled to compensation [7][8] Summary by Category Class Action Details - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [3] - No class has been certified yet, meaning investors are not represented by counsel unless they retain one [2] Allegations Against the Company - The lawsuit claims that Bolt overstated the effectiveness of BDC-1001 and its product pipeline, which could lead to significant operational risks [8] - The company allegedly failed to disclose that BDC-1001 was unlikely to meet its success criteria, impacting its commercial prospects [8]